Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
The DOI matches its Crossref record; 37 of the 51 references it cites were found in a registry or an index.
Abstract
CONTEXT: The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor. OBJECTIVE: The aim of this study is to assess the safety, tolerability, and efficacy of intranasal PYY(3-36) to induce weight loss in obese patients. DESIGN: The study was designed as a randomized, 2-wk, single-blind placebo run-in followed by a 12-wk double-blind, placebo-controlled treatment period. SETTING: The study was set within a private and institutional practice. PATIENTS: A total of 133 obese patients (body mass index, 30-43 kg/m(2); age, 18-65 yr) participated in the study. INTERVENTION: Placebo or 200- or 600-microg PYY(3-36) was administered as an intranasal spray 20 min before breakfast, lunch, and dinner in conjunction with a hypocaloric diet and exercise. MAIN OUTCOME MEASURE: Body weight was the main outcome measure. RESULTS: The number of patients completing 12 wk on the drug was 38 of 43 (88%), 31 of 44 (70%), and 12 of 46 (26%) for placebo, 200 microg three times a day (t.i.d.) and 600 microg t.i.d., respectively. In the 600 microg t.i.d. group, 27 of 46 (59%) patients discontinued due to nausea and vomiting. Among all randomized patients who took at least one drug dose and had a postbaseline measurement, the mean body weight change from baseline was -2.8, -3.7, and -1.4 kg for placebo, 200 and 600 microg, respectively. The least squares mean difference (95% confidence interval) between placebo and 200 microg was -0.9 (-2.6, 0.7) kg (P = 0.251). A difference of 2.11 kg was sought. No meaningful inference can be drawn from the few patients who completed the study on 600 microg. CONCLUSIONS: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [94]
In the citing paper
“Some PYY agents evaluated for monotherapy of obesity resulted in unacceptable nausea and vomiting and limited weight reduction [165,168].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [168]
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Human distribution and release of a putative new gut hormone, peptide YY
Adrian, T. E., Ferri, G.-L., Bacarese-Hamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90211-2 · Cited by 1,065
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Tatemoto, K., & Mutt, V. (1980) · Nature · doi:10.1038/285417a0 · Cited by 659
Attenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety
le Roux, C. W., Batterham, R. L., Aylwin, S. J. B., Patterson, M., Borg, C. M., Wynne, K. J., Kent, A., Vincent, R. P., Gardiner, J., Ghatei, M. A., et al. (2006) · Endocrinology · doi:10.1210/en.2005-0972 · Cited by 552
The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431
Korner, J., Bessler, M., Cirilo, L. J., Conwell, I. M., Daud, A., Restuccia, N. L., & Wardlaw, S. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1076 · Cited by 417
Research works printed but not linked: 2
- Batterham, 2003, Inhibition of food intake in obese subjects by peptide YY3–36., N Engl J Med, 349, 941
- Wyss, 1998, 76, 363
Cited by
Items 101–163 of 163
High expression of NPY receptors in the human testis
Körner, M., Waser, B., Thalmann, G. N., & Reubil, J. C. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.01.021 · Cited by 13
Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats
Nadkarni, P. P., Costanzo, R. M., & Sakagami, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01363.x · Cited by 14
“6 mg three times a day was discontinued in 59% of the obese subjects in a clinical study because of nausea and vomiting [23].”
BackgroundTackling obesity: new therapeutic agents for assisted weight loss
McFarlane, S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s6552 · Cited by 14
Approaches to the pharmacological treatment of obesity
Salem, V., & Bloom, S. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15
Mönkäre, J., Hakala, R. A., Kovalainen, M., Korhonen, H., Herzig, K., Seppälä, J. V., & Järvinen, K. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.09.011 · Cited by 18
“, the intranasal [19] and peroral [20] routes.”
BackgroundThe role of gut microbiota in anorexia induced by T-2 toxin
Huang, T., Li, A., Zhang, S., Fan, J., Hua, Z., Wang, X., Zhang, C., & Yang, X. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116612 · Cited by 12
The pharmacological treatment of obesity: Past, present and future
Simonyi, G., Pados, G., Medvegy, M., & Bedros, J. R. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29317 · Cited by 16
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 13
Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder
Geliebter, A., Ochner, C. N., & Aviram-Friedman, R. (2008) · American Journal of Lifestyle Medicine · doi:10.1177/1559827608317358 · Cited by 13
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
“Unfortunately, this intervention did not yield clinically significant decreases in caloric intake in a randomized clinical trial [125].”
Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems
Fong, T. M. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.321 · Cited by 10
“However, a statistically significant effect on body weight was not observed at either dose [30] .”
BackgroundTherapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 13
“Similarly, a pharmacologic formulation of PYY(3-36) failed because of side-effects (nausea and vomiting) [78].”
BackgroundSignals Arising from the Gastrointestinal Tract that Affect Food Intake
Purhonen, A. (2008) · Cited by 10
Pharmacological Treatment of the Overweight Patient
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-431-5_9 · Cited by 9
Can Bayliss and Starling gut hormones cure a worldwide pandemic?
Scott, R., Tan, T., & Bloom, S. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272955 · Cited by 10
“Despite these gastrointestinal side-effects, this dose did not produce significant weight loss (Gantz et al. 2007).”
BackgroundValsamakis, G., Lois, K. B., Kumar, S., & Mastorakos, G. P. (2014) · Clinical Obesity · doi:10.1111/cob.12064 · Cited by 7
“Despite evidence of significant reduction of calorie intake, the weight loss efficacy of PYY is still not documented (64).”
BackgroundPeptide YY: obesity's cause and cure?
Tschöp, M. H., & Ravussin, É. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00568.2007 · Cited by 7
“reported a randomized, 2-wk, single-blind, placebo run-in study, which was followed by a 3-mo double-blind, placebo-controlled trial to test the tolerability, safety, and efficacy of PYY in 133 obese patients (3).”
BackgroundMethodInfluentialEmerging Pharmacotherapies to Fight Obesity and Related Disorders
Handjieva‐Darlenska, T. (2014) · Journal of Obesity & Weight loss Therapy · doi:10.4172/2165-7904.1000226 · Cited by 6
“Intranasal administration has also been investigated in humans but the experiment failed to give any positive outcomes [30].”
BackgroundTargeting the Enteroendocrine System for Treatment of Obesity
Miedzybrodzka, E. L., Gribble, F. M., & Reimann, F. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_583 · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
Gut hormones regulating appetite and metabolism
McGowan, B. M., & Bloom, S. R. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2007.10.004 · Cited by 5
The role of PYY in improving insulin resistance
Liu, C., Na, R., Zhang, H., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1784709 · Cited by 6
Brain Related Gut Peptides – A Review
Manoharan, N., Jayamurali, D., Parasuraman, R., & Govindarajulu, S. N. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220920150127 · Cited by 4
Sizing Up Pharmacotherapy for Obesity
Valentino, M. A., Terzic, A., & Waldman, S. A. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00191.x · Cited by 6
Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity
Valentino, M. A., Colón‐González, F., Lin, J. E., & Waldman, S. A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.33 · Cited by 5
Respuesta secretora de PYY1-36 y PYY3-36 en sujetos normales tras la ingesta de una comida mixta
Penín, M., Fontán, M. P., Buela, J. G., Isidro, M. L., Martínez, T. D. R. F., Outeiriño, E., Rodríguez–Carmona, A., Sangiao‐Alvarellos, S., Vidal, O., & Cordido, F. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)72793-1 · Cited by 5
“Estudiamos a 8 sujetos sanos, 4 mujeres y 4 varones, con una mediana (intervalo) de edad de 53 (36-59) años.”
BackgroundSignificance of neuroendocrine systems and the gut-brain axis (GBA) in the regulation of obesity
Zhao, H., Li, Y., Cheng, R., Wang, Y., Ma, L., & Chen, W. (2026) · PeerJ · doi:10.7717/peerj.20400 · Cited by 5
Péptido YY: una nueva estrategia para el tratamiento de la obesidad
Giménez‐Palop, O., & Caixàs, A. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)70186-x · Cited by 4
Drug targets modulating the gut-appetite-metabolism axis
Näslund, E. B., & Hellström, P. M. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2007.10.008 · Cited by 2
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Current status and perspectives in the treatment of Prader-Willi syndrome
Badiu, C., & Mărginean, O. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.884921 · Cited by 1
“use of PYY in simple obesity suppresses appetite and decreases food intake, while longer intranasal use, up to 12 weeks, does not bring any beneficial effects [52], so it could not be a good choice for PWS patients.”
BackgroundIncretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
Peripheral Modulators of Appetite in Eating Disorders
Procházková, P., Roubalová, R., & Papežová, H. (2023) · Springer eBooks · doi:10.1007/978-3-030-97416-9_113-1 · Cited by 2
Shao, J., Chen, M., Kuehl, P. J., & Hochhaus, G. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1593443 · Cited by 1
“[29] to better analyze PK parameters of PYY(3–36) (Gantz et al.”
BackgroundThe Physiology and Pharmacology of Diabetic Gastropathy Management
Dolan, R. D., Rohani, T. S., Muttineni, D., & Mashimo, H. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00045-1 · Cited by 1
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_25 · Cited by 3
Obesity Insulin Resistance and Gut Hormones
Proietto, J. (2009) · Wiley eBooks · doi:10.1002/9781444307627.ch14
Pelleymounter, M. A., Wang, Y., & Lee, N. (2011) · Wiley eBooks · doi:10.1002/9783527636730.ch12
What's new in…..obesity. Neuroendocrinology of obesity and the potential for new treatments
Field, B. C. T. (2012) · Medicine · doi:10.1016/j.mpmed.2012.10.003
JCL Roundtable: Clinical management of individuals with obesity
Brown, W. V., Bays, H. E., & Bray, G. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.005 · Cited by 1
Therapies for Obesity Management
Tran-Kerr, K. (2015)
Takenoya, F., Hirako, S., Kageyama, H., Nonaka, N., & Shioda, S. (2013) · Drug Delivery System · doi:10.2745/dds.28.300
Mietlicki‐Baase, E. G., & Hayes, M. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-1 · Cited by 2
2. Drug Strategies for the Treatment of Obesity -Clinical Application of Gut-brain Peptides.
Nakazato, M. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.928
Bioactive Peptides in Gut–Brain Signaling
Näslund, E. B., Grybäck, P., & Hellström, P. M. (2009) · CRC Press eBooks · doi:10.1201/9781420061161-c12
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“long acting agonists at the PYY or OXM receptors, although these are in phase I development(279-281).”
BackgroundANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA
Tamargo, J. L. (2016)
Humans – The Ultimate Model for the Study of Neuroendocrine Systems
Yang, L., Izzi‐Engbeaya, C. N., & Dhillo, W. S. (2018) · Wiley eBooks · doi:10.1002/9781119391128.ch17
Perspectives of Metabolic Surgery
Marjanović, G., & Karcz, W. K. (2012) · Springer eBooks · doi:10.1007/978-3-642-02411-5_33
Miyanaga, S., Ojima, E., Michiwa, Y., Nakano, T., Higashi, K., Nishida, H., Nishi, K., & Ooi, A. (2017) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000209
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f4f084
Mietlicki‐Baase, E. G., & Hayes, M. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_25
Holzer, P. D., & Farzi, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65827-0 · Cited by 1
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-2
Peripheral Modulators of Appetite in Eating Disorders
Procházková, P., Roubalová, R., & Papežová, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-46096-8_113
Holzer, P. D., & Farzi, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00401-5 · Cited by 1
Beyond GLP-1: underexplored peptide–receptor systems as the next frontier in drug discovery
Niazi, S. K. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1792418
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“Studies on intravenous PYY showed reduced food intake [258], while nasal spray was ineffective [259].”
OBESITY: NEW MECHANISMS AND TRANSLATIONAL PARADIGMS
Gaich, G. A., & Moller, D. E. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.006
Metadata
- Authors
- Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., Wagner, J. A., MacNeil, D. J., Heymsfield, S. B., & Amatruda, J. M.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Gantz, Ira
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1754-1757
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118965081
- Cited by
- 163
- References
- 51
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 10 · 2012: 13
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- PYY3-36, intranasal administration, weight loss, obesity, satiety hormones, hypocaloric diet, physical activity, nausea and vomiting, drug safety and tolerability, appetite regulation, gastrointestinal hormones, obesity pharmacotherapy, dose comparison, treatment discontinuation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Body Weight, Diet, Reducing, Dose-Response Relationship, Drug, Double-Blind Method, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Peptide Fragments, Weight Loss, Body Mass Index, Treatment Outcome, Peptide YY
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.